Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Acotec Scientific Holdings / Equity Capital Markets

<p>Acotec, a leading China-based peripheral-vascular interventional device company, started book building to raise up to USD 210m via a Hong Kong listing.</p><p>In our previous note, we looked at two core drug coated balloon products of the company, namely the AcoArt Orchid &amp; Dhalia for the above the knee artery stenosis and AcoArt Tulip &amp; Litos for the below the knee stenosis. Both AcoArt Orchid &amp; Dhalia, and AcoArt Tulip &amp; Litos reported efficacy that could be potentially better than its benchmark product. Thanks to its early mover advantage, the AcoArt Orchid &amp; Dhalia had a dominant market share. The main growth driver of the company's core product will be increasing penetration rate and indication expansion. Besides the DCB products, we think the company's product pipeline is not exciting. The company has a good management team but the pre-IPO investors are overall mediocre.</p><p>In this note, we provide an update for the book building. We think the risk reward does not warrant a participation at the high end.</p>

Acotec, a leading China-based peripheral-vascular interventional device company, started book building to raise up to USD 210m via a Hong Kong listing.In our previous note, we looked at two core drug coated balloon products of the company, namely the AcoArt Orchid &amp; Dhalia for the above the knee artery stenosis and AcoArt Tulip &amp; Litos for the below the knee stenosis. Both AcoArt Orchid &amp; Dhalia, and AcoArt Tulip &amp; Litos reported efficacy that could be potentially better than its benchmark product. Thanks to its early mover advantage, the AcoArt Orchid &amp; Dhalia had a dominant market share. The main growth driver of the company's core product will be increasing penetration rate and indication expansion. Besides the DCB products, we think the company's product pipeline is not exciting. The company has a good management team but the pre-IPO investors are overall mediocre.In this note, we provide an update for the book building. We think the risk reward does not warrant a participation at the high end.

Acotec (先瑞达) IPO: Risk-Reward Does Not Warrant Participation

Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Shanghai HeartCare Medical Technology / Equity Capital Markets

<p>The neuro-interventional medical device company, <a href="https://www.smartkarma.com/entities/shanghai-heartcare-medical-technology-corporation-limited" target="_blank" data-smartkarma-citation="entities:32192:1" rel="noopener">Shanghai HeartCare Medical Technology (6609 HK)</a>  has announced the terms for its upcoming Hong Kong IPO. The company plans to issue 6.6m shares (20.9% of the total outstanding shares post-IPO) at an indicative IPO price range of HK$160-171 per share and will raise net proceeds of HK$980.6m (US$125.9m) at the midpoint of the IPO price range of HK$165.5 per share at a market capitalisation of HK$5.2bn and a post-money EV of HK$3.8bn.</p><p>Shanghai Heartcare plans to use approx. 45.3% of the net IPO proceeds on funding the ongoing R&amp;D, manufacturing and marketing of its core products Captor and LAA Occluder in China. The company also plans to spend about 40% of the net IPO proceeds on developing its other product candidates in the pipeline and another 4.8% of the net proceeds on continued expansion of the company’s product portfolio.</p><p>The company has entered into cornerstone investment agreements (with 10 investors) for an aggregate amount of HK$513.15m (US$66m) that represents 46.96% of the offer shares (at the midpoint) with lake Bleu Prime Healthcare Master Fund Limited (US$10m), Boyu Capital Opportunities Fund (US$10m), Octagon Investments Master Fund (US$10m), Aspex Master Fund (US$10m) and several other investors.  </p>

The neuro-interventional medical device company, Shanghai HeartCare Medical Technology (6609 HK)  has announced the terms for its upcoming Hong Kong IPO. The company plans to issue 6.6m shares (20.9% of the total outstanding shares post-IPO) at an indicative IPO price range of HK$160-171 per share and will raise net proceeds of HK$980.6m (US$125.9m) at the midpoint of the IPO price range of HK$165.5 per share at a market capitalisation of HK$5.2bn and a post-money EV of HK$3.8bn.Shanghai Heartcare plans to use approx. 45.3% of the net IPO proceeds on funding the ongoing R&amp;D, manufacturing and marketing of its core products Captor and LAA Occluder in China. The company also plans to spend about 40% of the net IPO proceeds on developing its other product candidates in the pipeline and another 4.8% of the net proceeds on continued expansion of the company’s product portfolio.The company has entered into cornerstone investment agreements (with 10 investors) for an aggregate amount of HK$513.15m (US$66m) that represents 46.96% of the offer shares (at the midpoint) with lake Bleu Prime Healthcare Master Fund Limited (US$10m), Boyu Capital Opportunities Fund (US$10m), Octagon Investments Master Fund (US$10m), Aspex Master Fund (US$10m) and several other investors.  

Shanghai Heartcare IPO: DCF Offers Decent Upside but Mind the Ongoing Lawsuit with Medtronic

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

<div><p><a href="https://www.smartkarma.com/entities/shanghai-heartcare-medical-technology-corporation-limited" target="_blank" data-smartkarma-citation="entities:32192:1" rel="noopener">Shanghai HeartCare Medical Technology (6609 HK)</a> is a China-based neuro-interventional medical device manufacturer with a product portfolio that spans the treatment and prevention of ischemic stroke to the treatment of haemorrhagic stroke. HeartCare’s product portfolio consists of a total of 23 commercialised products and product candidates, including four ischemic stroke treatment devices with NMPA approval.</p></div><div><p>HeartCare has launched an HKEx IPO to raise net proceeds of HK$980.6 million ($126 million) at the mid-point of the IPO price range of HK$160.00-171.00 per share. Ten cornerstone investors will subscribe for $66 million worth of the offer shares (46.96% of the offer shares at the mid-point). Pricing will be finalised on 13 August and the shares will list on 20 August.</p></div><div><p>In <a href="https://www.smartkarma.com/insights/shanghai-heartcare-medical-ipo-initiation-surviving-strokes" target="_blank" data-smartkarma-citation="insights:50331" rel="noopener">Shanghai HeartCare Medical IPO Initiation: Surviving Strokes</a>, we opined that HeartCare only started to generate revenue in 1Q20 through the commercialisation of two products (SupSelek and ExtraFlex). Captor thrombectomy device, a core product, was commercialised in December 2020 and Fullblock balloon guiding catheter was commercialised in April 2021. HeartCare aims to commercialise nine currently late-stage product candidates in 2021 and ten currently earlier-stage product candidates between 2022 and 2025. With a strong near-term commercialisation pipeline, HeartCare has shifted from a concept to a revenue-generating stock. We concluded that HeartCare’s product portfolio is attractive.  </p></div><div><div>
<p>HeartCare is braving the moribund IPO market for Chinese stocks by seeking to raise a lower amount than the original target of a $300 million raise. Despite the sell-off on Chinese names, <a href="https://www.smartkarma.com/entities/zylox-tonbridge-medical-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:32974:1" rel="noopener">Zylox-Tonbridge Medical Technology (2190 HK)</a>, a peer, is trading 9% above its IPO price (listed 5 July 2021), suggesting that sentiment on the Chinese medical devices sector remains positive.  </p>
<div class="content-highlight"><p>Our base-case DCF valuation is HK$186.51 per share, which is a 13% upside to the mid-point of the IPO price range of HK$160.00-171.00 per share. Consequently, we would participate in the IPO. </p></div>
</div></div>

Shanghai HeartCare Medical Technology (6609 HK) is a China-based neuro-interventional medical device manufacturer with a product portfolio that spans the treatment and prevention of ischemic stroke to the treatment of haemorrhagic stroke. HeartCare’s product portfolio consists of a total of 23 commercialised products and product candidates, including four ischemic stroke treatment devices with NMPA approval.HeartCare has launched an HKEx IPO to raise net proceeds of HK$980.6 million ($126 million) at the mid-point of the IPO price range of HK$160.00-171.00 per share. Ten cornerstone investors will subscribe for $66 million worth of the offer shares (46.96% of the offer shares at the mid-point). Pricing will be finalised on 13 August and the shares will list on 20 August.In Shanghai HeartCare Medical IPO Initiation: Surviving Strokes, we opined that HeartCare only started to generate revenue in 1Q20 through the commercialisation of two products (SupSelek and ExtraFlex). Captor thrombectomy device, a core product, was commercialised in December 2020 and Fullblock balloon guiding catheter was commercialised in April 2021. HeartCare aims to commercialise nine currently late-stage product candidates in 2021 and ten currently earlier-stage product candidates between 2022 and 2025. With a strong near-term commercialisation pipeline, HeartCare has shifted from a concept to a revenue-generating stock. We concluded that HeartCare’s product portfolio is attractive.  
HeartCare is braving the moribund IPO market for Chinese stocks by seeking to raise a lower amount than the original target of a $300 million raise. Despite the sell-off on Chinese names, Zylox-Tonbridge Medical Technology (2190 HK), a peer, is trading 9% above its IPO price (listed 5 July 2021), suggesting that sentiment on the Chinese medical devices sector remains positive.  
Our base-case DCF valuation is HK$186.51 per share, which is a 13% upside to the mid-point of the IPO price range of HK$160.00-171.00 per share. Consequently, we would participate in the IPO. 


Shanghai HeartCare Medical IPO: Valuation Insights

<p>Shanghai HeartCare is a neuro-interventional medical device pioneer in China. It has four products approved for marketing and expects 9 products to commercialize in 2021, as well 10 products to commercialize between 2022 and 2025. The company launched book building to raise up to USD 145m via a Hong Kong listing.</p><p>In our previous note, we looked at the company's two core products Captor and LAA Occluder. We think the Captor, a stent retrieving thrombectomy device, is the main selling point of the deal given its decent efficacy and safety data and it has already been approved by the NMPA. Market structure for Captor is characterized by the early stage of growth and dominance by MNC players and the company's product is the first approved domestic product with commendable data from head-to-head clinical trials. The company's management are mainly ex-employee from Microport Scientific, a leading international medical device player in China.</p><p>In this note, we provide an update for the book building. We think the upside is substantial barring negative outcomes from the legal proceedings with Medtronic.</p>

Shanghai HeartCare is a neuro-interventional medical device pioneer in China. It has four products approved for marketing and expects 9 products to commercialize in 2021, as well 10 products to commercialize between 2022 and 2025. The company launched book building to raise up to USD 145m via a Hong Kong listing.In our previous note, we looked at the company's two core products Captor and LAA Occluder. We think the Captor, a stent retrieving thrombectomy device, is the main selling point of the deal given its decent efficacy and safety data and it has already been approved by the NMPA. Market structure for Captor is characterized by the early stage of growth and dominance by MNC players and the company's product is the first approved domestic product with commendable data from head-to-head clinical trials. The company's management are mainly ex-employee from Microport Scientific, a leading international medical device player in China.In this note, we provide an update for the book building. We think the upside is substantial barring negative outcomes from the legal proceedings with Medtronic.

Heartcare (心玮医疗) IPO: Decent Upside Barring Negative Lawsuit Outcomes

<p>Acotec, a leading China-based peripheral-vascular interventional device company, is looking to raise up to USD 300m via a Hong Kong listing.  </p><p>In our previous note, we looked at two core drug coated balloon products of the company, namely the AcoArt Orchid &amp; Dhalia for the above the knee artery stenosis and AcoArt Tulip &amp; Litos for the below the knee stenosis. Both AcoArt Orchid &amp; Dhalia, and AcoArt Tulip &amp; Litos reported efficacy that could be potentially better than its benchmark product. Thanks to its early mover advantage, the AcoArt Orchid &amp; Dhalia had a dominant market share. The main growth driver of the company's core product will be increasing penetration rate and indication expansion. Besides the DCB products, we think the company's product pipeline is not exciting. The company has a good management team but the pre-IPO investors are overall mediocre.</p><p>In this note, we will provide our thoughts on the company's valuation.</p>

Acotec, a leading China-based peripheral-vascular interventional device company, is looking to raise up to USD 300m via a Hong Kong listing.  In our previous note, we looked at two core drug coated balloon products of the company, namely the AcoArt Orchid &amp; Dhalia for the above the knee artery stenosis and AcoArt Tulip &amp; Litos for the below the knee stenosis. Both AcoArt Orchid &amp; Dhalia, and AcoArt Tulip &amp; Litos reported efficacy that could be potentially better than its benchmark product. Thanks to its early mover advantage, the AcoArt Orchid &amp; Dhalia had a dominant market share. The main growth driver of the company's core product will be increasing penetration rate and indication expansion. Besides the DCB products, we think the company's product pipeline is not exciting. The company has a good management team but the pre-IPO investors are overall mediocre.In this note, we will provide our thoughts on the company's valuation.

Acotec (先瑞达) Pre-IPO: Thoughts on Valuation

China

Leading player in the neuro- and peripheral-vascular interventional medical device market in China.

Zylox-Tonbridge Medical Technology (2190 HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zylox-Tonbridge Medical Technology (2190 HK)

Acotec (先瑞达) IPO: Risk-Reward Does Not Warrant Participation

We look at the deal term and are of the view that the risk reward does not warrant a participation on Acotec at the high end.

Ke Yan, CFA, FRM

Shanghai Heartcare IPO: DCF Offers Decent Upside but Mind the Ongoing Lawsuit with Medtronic

Our DCF valuation offers a price per share of HK$182.78 which is 6.9% higher than the upper end of the company’s indicative IPO price range of...

Shifara Samsudeen, ACMA, CGMA

Shanghai HeartCare Medical IPO: Valuation Insights

Our base-case DCF valuation is HK$186.51 per share, which is a 13% upside to the mid-point of the IPO price range of HK$160.00-171.00 per share.

Arun George

Heartcare (心玮医疗) IPO: Decent Upside Barring Negative Lawsuit Outcomes

We provide an update for HeartCare's book building. We think the upside is substantial barring negative outcomes from the legal proceedings with...

Ke Yan, CFA, FRM

Acotec (先瑞达) Pre-IPO: Thoughts on Valuation

We provide our forecast and valuation for the company's two key products AcoArt Orchid & Dhalia, as well as AcoArt Tulip & Litos.

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)